According to the agreement, ICU Medical will buy Pfizer’s Hospira Infusion Systems business for $400 million in newly issued shares and $600 million in cash. Pfizer bought Hospira Infusion Systems in February for a total enterprise value of $17 billion .
The transaction gives Pfizer a 16.6 percent stake in ICU Medical. Pfizer will also be able to nominate one of the company’s directors to ICU Medical’s board of directors, according to the article. Pfizer reportedly agreed to certain restrictions regarding the transfer of its ICU Medical shares for 18 months following the close of the deal, according to the article.
The agreement is subject to regulatory approval. Officials from both companies expect the deal to close in the first quarter of 2017.
More articles on transactions and valuations:
Chinese billionaire claims he does not want to control CHS
5 things to know about freestanding emergency departments
Ardent, LHP Hospital Group merger to form 2nd largest private, for-profit hospital chain
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
